Special computerized methods and systems are required for detection of malignancy associated changes (MAC). In addition, special filter devices for depositing cytologic material in the cytometer are necessary. Two members of our research programme group were involved in the development of these methods, systems and devices which are now patented in the USA.
F.32 International patent
COBISS.SI-ID: 458363515451The members of the programme group organized the 20th International Meeting of the Adriatic Society of Pathology, which was held in June 2005. The topics included Pathology of Head & Neck, Dermatopathology and Technological Advances in Pathology; there were 33 oral presentations.
B.01 Organiser of a scientific meeting
COBISS.SI-ID: 19814873The use of tissue microarray (TMA) technology may substantially reduce the costs of HER2 determination in breast cancer. We were among the first to introduce the TMA technique in routine work. Analysis of more than 1000 samples showed that HER2 status can be accurately assessed on TMAs in approximately 80% of cases. The costs of the necessary reagents were reduced by 75%. TMA approach makes parallel testing of each tumor by IHC and FISH affordable, thus allowing better characterization of HER2 status and, consequentially, more appropriate treatment of breast cancer patients.
F.17 Transfer of existing technologies, know-how, methods and procedures into practice
COBISS.SI-ID: 588155We analyzed malignancy associated changes (MACs) in normal buccal mucosa cells of lung and breast cancer patients and their relationship to tumor subtype, stage and size. The study showed that lung and breast cancer induce MACs in normal buccal mucosa cells. The classifiers based on the selected nuclear features correctly recognized )80% of lung and breast cancer cases. The results indicate that MAC detection is not dependent on the tumor subtype, stage or size. The presence of MACs in buccal mucosa cells offers the potential for developing a new noninvasive cancer screening test.
F.21 Development of new health/diagnostic methods/procedures
COBISS.SI-ID: 272507A quantitative detection assay for analysis of platelet glycoprotein GPIIIa gene expression was developed. The assay uses two fluorescently labeled TaqMan MGB probes to detect the polymorphic site in GPIIIa nucleotide sequence, leading to antigens HPA-1a and HPA-1b. This newly developed real-time quantitative PCR assay is a sensitive, reproducible and reliable method. It is suitable for studying different stages of megakaryopoiesis and determining differences in the GPIIIa expression level between normal and pathological megakaryocytic differentiation pathways.
F.21 Development of new health/diagnostic methods/procedures
COBISS.SI-ID: 24179417Special computerized methods and systems are required for detection of malignancy associated changes (MAC). In addition, special filter devices for depositing cytologic material in the cytometer are necessary. Two members of our research programme group were involved in the development of these methods, systems and devices which are now patented in the USA.
F.32 International patent
The members of the programme group organized the 20th International Meeting of the Adriatic Society of Pathology, which was held in June 2005. The topics included Pathology of Head & Neck, Dermatopathology and Technological Advances in Pathology; there were 33 oral presentations.
B.01 Organiser of a scientific meeting